Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07699939 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma

Study acronym: PLATANUS
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 2 of 18 sitesv4
  2. Recruitment opened
    • Site details revised at 18 of 18 sites
    v3
  3. Eligibility criteria expanded, about 19 words
    • Study title shortened, about 6 words
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the clinical efficacy of perioperative treatment with S-1 + oxaliplatin (SOX)+ HLX10 compared with SOX as the control in patients with cT3-4N1-3M0 PD-L1-positive (CPS ≥ 5) locally advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma, in a placebo-controlled, double-blind, randomized phase II investigator-initiated clinical study.
Trial Details
NCT Number NCT07699939
Lead Sponsor National Cancer Center, Japan
Conditions
(from sponsor)		 Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Related terms Adenocarcinoma
Enrollment 136 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov